Tag Archives: Disease Modification

Development of Standardised Intervention Outcome Measures for Dementia Prevention (PLoS One / HTA)

Posted on July 25, 2017 by Dementia and Elderly Care News

Summary The following articles present work towards establishing a consensus on the most suitable outcomes to be measured when assessing “disease modification” (or the lack of it) in response to interventions intended to delay or prevent the progress of dementia. … Continue reading →

Posted in Alzheimer's Society, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, Mental Health, Models of Dementia Care, Quick Insights, Standards, Systematic Reviews, UK | Tagged Activities of Daily Living (ADLs), Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer's Society, Alzheimer’s Disease Clinical Trials, and Health Psychology: University College London, Assessment of Quality of Life, Aston Research Centre for Healthy Ageing: Aston University, Aston University, Bangor University, Biological Markers, Biomarkers, Brighton and Sussex Medical School, Cambridge Institute of Public Health: University of Cambridge, Camden and Islington NHS Foundation Trust, Cardiff University, Centre for Dementia Studies: Brighton and Sussex Medical School, Centre for Public Health: Queen's University Belfast, Centre for Research in Primary and Community Care: University of Hertfordshire, Clinical Dementia Rating (CDR), Clinical Dementia Rating Scale, Core Outcome Measures in Effectiveness Trials, Dementia Quality of Life (DEMQOL), Dementia Quality of Life Measure, Dementia Services Development Centre Wales: Bangor University, Department of Psychiatry and Psychotherapy: Ludwig-Maximilians-Universität München, Department of Psychiatry and Psychotherapy: Technische Universität München, Department of Psychiatry: University of Cambridge, Disability Assessment for Dementia-DAD, Disease Modification, Disease Modification Trials, Disease-Modifying Trials in Mild-to-Moderate Dementia, Division of Psychiatry: University College London, Division of Psychology and Language Sciences: University College London, Drug Trials Failure Rate, Faculty of Health and Social Care: University of Hull, Faculty of Medicine: Imperial College London, Germany, Health Technology Assessment (HTA) Programme, Health Technology Assessment Study, Health Technology Assessments, Imperial College London, Institute of Brain Behaviour and Mental Health: University of Manchester, Institute of Health and Society: Newcastle University, Institute of Mental Health: University of Nottingham, International Consortium for Health Outcomes Measurement, Kings College London, Leeds Beckett University, Ludwig-Maximilians-Universität München, Magnetic Resonance Imaging (MRI), Measurement of Successes and Failures of Dementia Treatments, Measuring the Impact of Interventions to Reduce Alzheimer’s Disease, Mini Mental State Examination (MMSE), National Institute for Health Research (NIHR), National Institute for Health Research: Health Technology Assessment Programme, Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory (NPI) Agitation / Aggression Scale, Neuropsychiatric Inventory Agitation / Aggression Domain (NPI), Neuropsychiatric Symptoms, Neuropsychiatric Symptoms in People With Dementia, Neuroscience Research Centre - St. George's: University of London, Newcastle University, NIHR Health Technology Assessment (HTA) Programme, NIHR HTA: Health Technology Assessment Programme, North Thames CLAHRC, Norwich Medical School: University of East Anglia, Nuffield Department of Population Health: University of Oxford, Opportunities for Standardisation, Outcome Measures for Disease-Modifying Trials in Mild-to-Moderate Dementia, Outcome Validation, Oxford Health NHS Foundation Trust, Patient and Public Involvement (PPI), PenCLAHRC: University of Exeter Medical School, Personal Social Services Research Unit: University of Manchester, Potential Treatment for Alzheimer’s Disease, Queen's University Belfast, Research Department of Clinical Educational, Research Institute for the Care of Older People (RICE): University of Bath, ScHARR: University of Sheffield, School of Clinical Sciences: University of Bristol, School of Health and Community Studies: Leeds Beckett University, School of Healthcare Sciences: Cardiff University, School of Medicine: University of Southampton, School of Psychology: University of Exeter, School of Public Health: Imperial College London, sMRI (Structural Magnetic Resonance Imaging), Standardisation, Systematic Reviews and Meta-Analyses, Technische Universität München, United Kingdom, University College London, University of Bath, University of Bristol, University of Cambridge, University of East Anglia, University of Exeter, University of Exeter Medical School, University of Hertfordshire, University of Hull, University of London, University of Manchester, University of Nottingham, University of Oxford, University of Sheffield, University of Southampton, University of Warwick, Warwick Clinical Trials Research Unit: University of Warwick, Wolfson Centre for Age-Related Diseases: King’s College London | Leave a comment

NICE Participation in European ROADMAP Project: Faster Access to Alzheimer’s Disease Drugs? (NICE)

Posted on January 12, 2017 by Dementia and Elderly Care News

Summary NICE is participating in the ROADMAP initiative, which is working on a sustainable platform for “real world” evidence generation concerning Alzheimer’s Disease and (hopefully) faster development of disease-modifying drugs. “The IMI (Innovative Medicines Initiative) is Europe’s largest public-private partnership, … Continue reading →

Posted in Commissioning, For Researchers (mostly), In the News, International, National, Quick Insights, UK, Universal Interest | Tagged Academia-Industry Partnerships, Big Data, Big Data for Better Outcomes Programme (IMI), Big Data Funding and Research, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Research, Disease Modification, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Treatments for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Electronic Health Records (EHRs), European ROADMAP Project, Global Leadership, Global Outlook, IMI (Innovative Medicines Initiative), IMI’s Big Data for Better Outcomes Programme, Innovative Medicines Initiative (IMI), International Collaborations, International Programmes, Leveraging Big Data, National Institute for Health and Care Excellence (NICE), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NICE’s Science Policy and Research Programme, Pan-European Collaborations, Partnership, Partnership and Collaboration, Partnership Working, Prof Carole Longson: National Institute for Health and Care Excellence (NICE), Professor Carole Longson: Director of Centre for Health Technology Evaluation at NICE, Professor John Gallacher: University of Oxford, Promisary Science, Publicly-Funded UK Big Data Research, Research and Innovation, Resource and Incentives, ROADMAP Initiative | Leave a comment

AAIC’s Curated Round-Up of Publications Related to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference / Alzheimer’s and Dementia)

Posted on July 30, 2016 by Dementia and Elderly Care News

Summary Not everyone will have been able to attend the Alzheimer’s Association International Conference in Toronto last week. The Alzheimer’s Association AAIC Press Office has been kind enough to provide a curated collection of associated publications, relating to the 2016 … Continue reading →

Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), Aboriginal and Torres Strait Islanders, Accelerating Medicines Partnership (AMP-AD), AD Genetics Consortium (ADGC), AddNeuroMed, ADNI Depression Study, Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Study, Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), Alzheimer's Disease Big Data DREAM Challenge 1, Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Alzheimer’s Therapy Clinical Trial Results, Alzheimers and Dementia, Argentina ADNI (Arg-ADNI), Australian ADNI, Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL), Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Brain Insulin and Insulin Receptors, Brain Insulin Resistance, Caregiver Burden and Dependence, Causes of Brain Insulin Resistance, China ADNI (C-ADNI), Chronic Traumatic Brain Injury, Clinical Dementia Rating–Sum of Boxes (CDR-SB), Cognitive Training, Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Initiative, CSF Biomarkers, DADE Investigator Group, DADE Study, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Department of Defense Alzheimer's Disease Neuroimaging Initiative, Dependence in AD in England (DADE), Dependence Scale (DS), Dialogue on Reverse Engineering Assessment and Methods (DREAM) Project, Dietary Recommendations, Disease Modification, Down Syndrome Biomarker Initiative, DREAM, Drug Development for Alzheimer's Disease, Early Treatment to Reduce Costs and Mortality, EPAD, Estrogen Receptor (ESR), Estrogen Receptor Polymorphisms and Incident Dementia, European ADNI (E-ADNI), European Medical Information Framework (EMIF), Food and Drug Administration (FDA)'s Guidance for Industry Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease, Formal Education and Complex Work, Framingham Heart Study, Frontotemporal Lobar Degeneration Neuroimaging Initiative, Genetic and Environmental Risk for AD Consortium (GERAD1), Global CEO Initiative for Alzheimer's Disease, Glucagon-Like Peptide-1 (GLP-1) Analogs, Imatinib Inhibition of Amyloid Precursor Protein (APP) In Humans, Imatinib Treatment and Aβ42 (In Humans), Impacts of ADNI, Incretin Mimetics, Innovative Medicine Initiative AD Research Platform, Insulin Receptor Substrate-1 (IRS-1) Signaling Pathway, Italo Monzino Foundation, Japanese ADNI (J-ADNI), Korean ADNI, Laboratory of Neuroimaging (LONI), Leuco-Methylthioninium (LMTM), Liraglutide (Victoza), LMTM Monotherapy, MBI Checklist (MBI-C), Mediterranean and DASH Diets, Mediterranean Diet, Mediterranean-DASH Intervention for Neurodegenerative Delay: MIND, Mediterranean-Dietary Approach to Systolic Hypertension (DASH) Diet, Mediterranean-Dietary Approach to Systolic Hypertension (DASH) Diet Intervention for Neurodegenerative Delay (MIND) Diet Score, Mild Behavioural Impairment (MBI), Mild Cognitive Impairment (MCI), MIND Diet, Monzino, Monzino 80-Plus Study, Neurodegeneration, Neurodegenerative Disease Research, North American Registry for Care and Research in MS, NPS Professional Interest Area (PIA), Parkinson's Progressive Markers Initiative (PPMI), Preclinical Alzheimer's Disease, Prevalence of Dementia in Aboriginal Australians, Prevalence of Dementia in China, Prevalence of Dementia in Oldest Old, Prodromal Alzheimer's Disease, Psychological Symptoms of Dementia (BPSD), Reduction of Systematic Sedation in Dementia Care, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Relationship Between Age and Dementia Prevalence, Research and Development, Research and Innovation, Research Commitment, Resilience, Rush University Medical Center, Sage Bionetworks, Smell Tests For Detection of Memory Decline and Dementia, Streptozotocin (STZ), Taiwan ADNI, TauRx Therapeutics, Toronto, Transforming Research and Clinical Knowledge in Huntington's Disease (TRACK-HD), Translational Research, Translational Research Into Alzheimer's Disease in Europe, Traumatic Brain Injury, Traumatic Brain Injury (TBI), Treating Brain Insulin Resistance, Update of the Alzheimer's Disease Neuroimaging Initiative, Urban and Regional Aboriginal Australians, Urban and Rural Areas of China, Worldwide Alzheimer's Disease Neuroimaging Initiative | Leave a comment

Tag Archives: Disease Modification

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites